Pregnancy: US Pregnancy category: D.
Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.
There is positive evidence of human fetal risk, but the benefits from use in pregnant women may be acceptable despite the risk (e.g., if the drug is needed in a life-threatening situation or for a serious disease for which safer drugs cannot be used or are ineffective).
Labor and delivery: Data is not available.
Lactation: It is not known if valsartan is excreted in human breast milk. Because of the potential for adverse effects on breast-feeding infants, decide whether to discontinue breast-feeding or discontinue valsartan, taking into account the importance of the drug to the mother.